The role of butyric acid in intestinal disease pathogenesis and treatment Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
butyric acid, sodium butyrate, inflammatory bowel disease, diverticular disease, irritable bowel syndrome
Main Article Content
Abstract
Butyric acid is one of short-chain fatty acids physiologically produced from non-absorbable dietary fiber by colonic microbiota. Multiple beneficial metabolic effects of butyric acid on human health, both at the intestinal and systemic level, are well documented. It serves as the main energy source for colonocytes and acts as a powerful cytoprotective, anti-inflammatory and trophic agent. The impaired butyrate production observed in many colonic conditions leads to intestinal barrier damages, bacterial translocation and dysregulation of immune and inflammatory response. The sodium salt of butyric acid (sodium butyrate) preparations are nowadays well recognized as potent dietary and therapeutic supplements with a wide spectrum of clinical indications in general and geriatric medicine, as well as in gastroenterology and surgery.
Article Details
How to Cite
Radwan , K., & Radwan , P. (2021). The role of butyric acid in intestinal disease pathogenesis and treatment. Medycyna Faktow (J EBM), 14(3(52), 250-257. https://doi.org/10.24292/01.MF.0321.6
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Roediger WW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980; 21: 793-8.
2. McNabney SM, Henagan TM. Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. Nutrients. 2017; 9: 1348.
3. Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr. 2019; 59(suppl 1): S130-S52.
4. Kotunia A, Pietrzak P, Guilloteau P et al. Kwas masłowy w przewodzie pokarmowym. Prz Gastroenterol. 2010; 5: 117-22.
5. Bach Knudsen KE, Lærke HN, Hedemann MS et al. Impact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and Inflammation. Nutrients. 2018; 10(10): 1499.
6. Hamer HM, Jonkers D, Venema K et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008; 27(2): 104-19.
7. Banasiewicz T, Borycka-Kiciak K, Dobrowolska-Zachwieja A et al. Kliniczne aspekty zastosowania kwasu masłowego w postępowaniu dietetycznym w chorobach jelit. Prz Gastroenterol. 2010; 5(6): 329-34.
8. Canani RB, Costanzo MD, Leone L et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011; 17(12): 1519-28.
9. Skrzydło-Radomańska B, Radwan P. Zastosowanie preparatów kwasu masłowego w gastroenterologii. Gastroenterol Prakt. 2013; 4(21): 34-5.
10. Couto MR, Gonçalves P, Magro F et al. Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. Pharmacol Res. 2020; 159: 104947.
11. Elce A, Amato F, Zarrilli F et al. Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells. Benef Microbes. 2017; 8(5): 841-7.
12. Sokol H, Seksik P, Furt JP et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. J Inflamm Bowel Dis Disord. 2009; 15(8): 1183-9.
13. Treem WR, Ahsan N, Shoup M et al. Fecal short-chain fatty acids in children with inflammatory bowel disease. Pediatr Gastroenterol Nutr. 1994; 18(2): 159-64.
14. Magnusson MK, Isaksson S, Öhman L. The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. Inflammation. 2020; 43(2): 507-17.
15. Tian Y, Xu Q, Sun L et al. Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. J Nutr Biochem. 2018; 57: 103-9.
16. Zhuang X, Li T, Li M et al. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 25(11): 1751-63.
17. Andoh A, Bamba T, Sasaki M. Physiological and antiinflamatory roles of diatery fiber and butyrate in intestinal. functions. J Parent Ent Nutr. 1999; 23: 70-3.
18. Segain J, de la Bletiere DR, Boureille A et al. Butyrate inhibits inflammatory responses through NFB inhibition: implications for Crohn’s disease. Gut. 2000; 47(3): 397-403.
19. Tobisawa Y, Imai Y, Fukuda M et al. Sulfation of colonic mucins by N-acetylglucosamine 6-O-sulfotransferase-2 and its protective function in experimental colitis in mice. J Biol Chem. 2010; 285: 6750-60.
20. Banasiewicz T, Borycka-Kiciak K, Kiciak A et al. Kwas masłowy w zapaleniach jelit. Prz Gastroenterol. 2010; 5(5): 251-7.
21. Vernia P, Monteleone G, Grandinetti G et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000; 45(5): 976-81.
22. Di Sabatino A, Morera R, Ciccocioppo R et al. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2005; 22(9): 789-94.
23. Krokowicz L, Kaczmarek BF, Krokowicz P et al. Sodium butyrate and short chain fatty acids in prevention of travellers’ diarrhoea: a randomized prospective study. Travel Med Infect Dis. 2014; 12(2): 183-8.
24. Krokowicz L, Stojcev Z, Kaczmarek BF et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis – a prospective randomized study. Int J Colorectal Dis. 2014; 29(3): 387-93.
25. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. M Colorectal Dis. 2013; 15(2): 204-9.
2. McNabney SM, Henagan TM. Short Chain Fatty Acids in the Colon and Peripheral Tissues: A Focus on Butyrate, Colon Cancer, Obesity and Insulin Resistance. Nutrients. 2017; 9: 1348.
3. Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr. 2019; 59(suppl 1): S130-S52.
4. Kotunia A, Pietrzak P, Guilloteau P et al. Kwas masłowy w przewodzie pokarmowym. Prz Gastroenterol. 2010; 5: 117-22.
5. Bach Knudsen KE, Lærke HN, Hedemann MS et al. Impact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and Inflammation. Nutrients. 2018; 10(10): 1499.
6. Hamer HM, Jonkers D, Venema K et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008; 27(2): 104-19.
7. Banasiewicz T, Borycka-Kiciak K, Dobrowolska-Zachwieja A et al. Kliniczne aspekty zastosowania kwasu masłowego w postępowaniu dietetycznym w chorobach jelit. Prz Gastroenterol. 2010; 5(6): 329-34.
8. Canani RB, Costanzo MD, Leone L et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011; 17(12): 1519-28.
9. Skrzydło-Radomańska B, Radwan P. Zastosowanie preparatów kwasu masłowego w gastroenterologii. Gastroenterol Prakt. 2013; 4(21): 34-5.
10. Couto MR, Gonçalves P, Magro F et al. Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. Pharmacol Res. 2020; 159: 104947.
11. Elce A, Amato F, Zarrilli F et al. Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells. Benef Microbes. 2017; 8(5): 841-7.
12. Sokol H, Seksik P, Furt JP et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. J Inflamm Bowel Dis Disord. 2009; 15(8): 1183-9.
13. Treem WR, Ahsan N, Shoup M et al. Fecal short-chain fatty acids in children with inflammatory bowel disease. Pediatr Gastroenterol Nutr. 1994; 18(2): 159-64.
14. Magnusson MK, Isaksson S, Öhman L. The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. Inflammation. 2020; 43(2): 507-17.
15. Tian Y, Xu Q, Sun L et al. Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. J Nutr Biochem. 2018; 57: 103-9.
16. Zhuang X, Li T, Li M et al. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 25(11): 1751-63.
17. Andoh A, Bamba T, Sasaki M. Physiological and antiinflamatory roles of diatery fiber and butyrate in intestinal. functions. J Parent Ent Nutr. 1999; 23: 70-3.
18. Segain J, de la Bletiere DR, Boureille A et al. Butyrate inhibits inflammatory responses through NFB inhibition: implications for Crohn’s disease. Gut. 2000; 47(3): 397-403.
19. Tobisawa Y, Imai Y, Fukuda M et al. Sulfation of colonic mucins by N-acetylglucosamine 6-O-sulfotransferase-2 and its protective function in experimental colitis in mice. J Biol Chem. 2010; 285: 6750-60.
20. Banasiewicz T, Borycka-Kiciak K, Kiciak A et al. Kwas masłowy w zapaleniach jelit. Prz Gastroenterol. 2010; 5(5): 251-7.
21. Vernia P, Monteleone G, Grandinetti G et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000; 45(5): 976-81.
22. Di Sabatino A, Morera R, Ciccocioppo R et al. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2005; 22(9): 789-94.
23. Krokowicz L, Kaczmarek BF, Krokowicz P et al. Sodium butyrate and short chain fatty acids in prevention of travellers’ diarrhoea: a randomized prospective study. Travel Med Infect Dis. 2014; 12(2): 183-8.
24. Krokowicz L, Stojcev Z, Kaczmarek BF et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis – a prospective randomized study. Int J Colorectal Dis. 2014; 29(3): 387-93.
25. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. M Colorectal Dis. 2013; 15(2): 204-9.